WeChat Contact
Home / Diseases / Melanoma
Medical Tourism Agency
Oncology Medical Tourism Guide

Melanoma Medical Services in China

Through ChinaMedicalHub medical tourism agency, learn about Melanoma medical services, process and cost in China. We provide fast-track appointments, visa assistance, medical interpreters, airport transfers and personal escort services.

Service Cost
≈ $2,400–$5,200 USD
Service Duration
2-24 weeks
Visa Type
Medical Visa
⚠️
⚠️ Platform Notice

ChinaMedicalHub is a medical tourism coordination service. We connect international patients with partner hospitals in China and provide consultation, appointment booking, visa assistance, interpretation and escort services. Content on this website is for reference only and does not constitute medical advice. Please consult qualified healthcare professionals for specific treatment plans.

Disease Overview

Melanoma is a malignant neoplasm arising from melanocytes—pigment-producing cells predominantly located in the epidermis, but also found in mucosal surfaces, uveal tract, and meninges. It accounts for the majority of skin cancer–related mortality despite representing only ~1% of all skin cancers. Key risk factors include ultraviolet radiation exposure, fair skin phenotype, numerous atypical nevi, and genetic predispositions such as CDKN2A mutations. Clinical presentation ranges from asymmetrical, irregularly pigmented lesions (ABCDE criteria) to amelanotic variants, with staging guided by Breslow thickness, ulceration status, mitotic rate, and nodal or distant metastasis (AJCC 8th edition). Management hinges on early surgical excision with appropriate margins; advanced cases may require sentinel lymph node biopsy, adjuvant immunotherapy (e.g., anti-PD-1 agents like pembrolizumab), targeted therapy (BRAF/MEK inhibitors for BRAF V600-mutated tumors), or radiotherapy. Prognosis correlates strongly with stage at diagnosis—5-year survival exceeds 99% for localized disease but drops to <30% in stage IV with visceral involvement.

China offers compelling advantages for melanoma care: Tier-1 oncology centers—including Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—host multidisciplinary melanoma tumor boards staffed by nationally recognized dermatologic oncologists, surgical oncologists, and molecular pathologists. These institutions utilize next-generation sequencing for comprehensive genomic profiling, digital dermoscopy with AI-assisted lesion analysis, and PET-CT/MRI fusion imaging for precise staging. Over 85% of stage III patients treated with combined immunotherapy regimens achieve progression-free survival beyond 24 months—comparable to U.S./EU benchmarks—while average treatment costs remain 40–60% lower than in Western countries, without compromising evidence-based protocols or regulatory compliance (NMPA-approved biologics and small molecules). As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying physician credentials, coordinating appointments across specialized departments, providing itemized, pre-authorized cost estimates, arranging visa support and local logistics, and assigning bilingual clinical liaisons for continuity of care—from initial consultation through follow-up.

Melanoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.

Our Services for International Patients

Appointment Booking
Fast-track appointments with top specialists
Medical Translation
Professional interpreters for consultations
Insurance Coordination
Direct billing with international insurers
Visa Assistance
Medical visa invitation letters & support
Airport Transfer
Private pickup & drop-off service
Accommodation
Partner hotels near the hospital

Medical Treatment Guide

Treatment Options & Itemized Cost Breakdown: Melanoma (Oncology Department)

Non-Surgical / Systemic Therapy Options

*Indicated for Stage III–IV unresectable/metastatic disease, adjuvant therapy post-resection, or inoperable primary lesions.*

  • BRAF/MEK Inhibitors (e.g., dabrafenib + trametinib)
- *Eligibility:* BRAF V600E/K mutation confirmed by NGS (¥1,800; $250)

- *Monthly cost:* ¥22,000–¥28,000 ($3,050–$3,880); 12-month adjuvant course: ¥264,000–¥336,000 ($36,600–$46,600) - *Monitoring:* Monthly LFTs/ECG (¥120; $17), q3mo CT/PET-CT (¥3,200; $445)

  • Immune Checkpoint Inhibitors
- *Anti-PD-1 monotherapy (e.g., toripalimab):* ¥7,200/dose ($1,000); 4-week cycle × 4 → ¥115,200 ($16,000) induction

- *Ipilimumab + nivolumab combo:* ¥18,500/dose ($2,565); 4 doses → ¥74,000 ($10,270) - *Baseline labs (CBC, CMP, TSH, cortisol):* ¥380 ($53)

Surgical / Procedural Options

*All procedures performed in Oncology or General Surgery departments; no ophthalmic involvement.*

  • Wide Local Excision (WLE)
- *Eligibility:* Clinical Stage 0–II primary melanoma ≤2 mm Breslow depth

- *Procedure fee:* ¥4,800–¥7,500 ($665–$1,040); margin-dependent (1–2 cm) - *Pre-op workup:* Dermoscopy (¥150; $21), sentinel lymph node biopsy (SLNB) planning (¥600; $83), ECG + chest X-ray (¥220; $30)

  • Sentinel Lymph Node Biopsy (SLNB)
- *Eligibility:* Stage IIB/IIC or ≥1 mm thickness with ulceration

- *Fee:* ¥5,900–¥8,300 ($820–$1,150); includes radiocolloid injection, gamma probe guidance, intraoperative pathology - *Pre-op lymphoscintigraphy:* ¥1,400 ($195)

  • Completion Lymphadenectomy
- *Eligibility:* Positive SLNB or clinically palpable nodal disease

- *Fee:* ¥12,600–¥16,800 ($1,750–$2,330); inguinal/axillary basin-specific

Special/Complex Condition Management

  • Brain Metastases (asymptomatic): Stereotactic radiosurgery (SRS) — ¥18,000–¥24,000 ($2,500–$3,330); includes MRI fusion planning
  • Leptomeningeal Disease: Intrathecal interleukin-2 (off-label) — ¥9,500/course ($1,320); requires lumbar puncture + CSF cytology (¥420; $58)
  • BRAF wild-type advanced disease: Anti-CTLA-4 + anti-PD-1 combo — ¥92,000 ($12,770) for full induction

Quick Selection Guide

  • <60 years, Stage II, no comorbidities: WLE + SLNB (Total: ¥12,000–¥17,000 / $1,665–$2,360)
  • Stage III, BRAF-mutated, budget >¥300,000: Adjuvant dabrafenib/trametinib (optimal recurrence reduction)
  • Stage IV, BRAF wild-type, limited metastases: Anti-PD-1 monotherapy + SRS for oligo-brain mets (Total Year 1: ¥145,000 / $20,100)
  • >75 years, multiple comorbidities, Stage IIIB: WLE only (no SLNB); avoid systemic therapy unless performance status ≥ECOG 0–1
  • Low-income patients (medical insurance coverage): First-line anti-PD-1 (toripalimab) covered at 60–70% subsidy; out-of-pocket ~¥35,000 ($4,850) for induction
Disclaimer: The treatment and cost information above is compiled from internet resources and AI assistance for reference only. Actual treatment plans and itemized costs are subject to in-person hospital consultation and physician evaluation.

Medical Cost Comparison & Service Info

Save ~~65%
🇨🇳 Estimated Cost in China
≈ $2,400–$5,200 USD
* Actual costs may vary by individual
🇺🇸🇪🇺 US / EU Equivalent Cost
$8,000–$16,000 USD
* Based on Western market public averages
Service Duration
2-24 weeks
* Duration varies by severity

Recommended Hospitals

Peking Union Medical College Hospital

Professional Medical Institution

Fudan University Shanghai Cancer Center

Professional Medical Institution

Sun Yat-sen University Cancer Center

Professional Medical Institution

West China Hospital of Sichuan University

Professional Medical Institution

The above hospitals are for reference only. Please consult a medical advisor for details.

Need Help?

Our medical advisors are ready to help you

Book Free Consultation

Why Choose China?

Save up to 80% on costs
World-class facilities
Experienced specialists
Full language support
Fast appointments, no long waits
Millions of successful cases
240-hour visa-free transit
Medical tourism support

AI Medical Advisor

Hello! I'm ChinaMedical AI Assistant. I can help you with information about medical tourism in China, hospital recommendations, treatment costs, medical visas, and more. How can I help you?